The global Liposome and Lipid Nanoparticle Finished Pharmaceuticals market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
Liposomes Drugs Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Liposome and Lipid Nanoparticle Finished Pharmaceuticals include Johnson & Johnson, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang, Zydus Cadila, TTY Biopharma and Pacira, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
This report aims to provide a comprehensive presentation of the global market for Liposome and Lipid Nanoparticle Finished Pharmaceuticals, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposome and Lipid Nanoparticle Finished Pharmaceuticals. This report contains market size and forecasts of Liposome and Lipid Nanoparticle Finished Pharmaceuticals in global, including the following market information:
Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global top five companies in 2023 (%)
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Liposome and Lipid Nanoparticle Finished Pharmaceuticals companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Segment Percentages, by Type, 2023 (%)
Liposomes Drugs
Lipid Nanoparticle Drugs
Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Segment Percentages, by Application, 2023 (%)
Hospital
Retail Pharmacy
Other
Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Liposome and Lipid Nanoparticle Finished Pharmaceuticals revenues in global market, 2019-2024 (estimated), ($ millions)
Key companies Liposome and Lipid Nanoparticle Finished Pharmaceuticals revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Pacira
Luye Pharma
Leadiant Biosciences
Ipsen
Sayre Therapeutics
Jazz
Alnylam
Bausch Health
Acrotech Biopharma
Takeda
Chiesi Farmaceutici
Gilead Sciences
Outline of Major Chapters:
Chapter 1: Introduces the definition of Liposome and Lipid Nanoparticle Finished Pharmaceuticals, market overview.
Chapter 2: Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals market size in revenue.
Chapter 3: Detailed analysis of Liposome and Lipid Nanoparticle Finished Pharmaceuticals company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Liposome and Lipid Nanoparticle Finished Pharmaceuticals in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Overall Market Size
2.1 Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size: 2023 VS 2030
2.2 Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Liposome and Lipid Nanoparticle Finished Pharmaceuticals Players in Global Market
3.2 Top Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Companies Ranked by Revenue
3.3 Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue by Companies
3.4 Top 3 and Top 5 Liposome and Lipid Nanoparticle Finished Pharmaceuticals Companies in Global Market, by Revenue in 2023
3.5 Global Companies Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Type
3.6 Tier 1, Tier 2 and Tier 3 Liposome and Lipid Nanoparticle Finished Pharmaceuticals Players in Global Market
3.6.1 List of Global Tier 1 Liposome and Lipid Nanoparticle Finished Pharmaceuticals Companies
3.6.2 List of Global Tier 2 and Tier 3 Liposome and Lipid Nanoparticle Finished Pharmaceuticals Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size Markets, 2023 & 2030
4.1.2 Liposomes Drugs
4.1.3 Lipid Nanoparticle Drugs
4.2 By Type - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue & Forecasts
4.2.1 By Type - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, 2019-2024
4.2.2 By Type - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, 2025-2030
4.2.3 By Type - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2023 & 2030
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.1.4 Other
5.2 By Application - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue & Forecasts
5.2.1 By Application - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, 2019-2024
5.2.2 By Application - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, 2025-2030
5.2.3 By Application - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2023 & 2030
6.2 By Region - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue & Forecasts
6.2.1 By Region - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, 2019-2024
6.2.2 By Region - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, 2025-2030
6.2.3 By Region - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, 2019-2030
6.3.2 US Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.3.3 Canada Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.3.4 Mexico Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, 2019-2030
6.4.2 Germany Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.4.3 France Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.4.4 U.K. Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.4.5 Italy Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.4.6 Russia Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.4.7 Nordic Countries Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.4.8 Benelux Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, 2019-2030
6.5.2 China Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.5.3 Japan Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.5.4 South Korea Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.5.5 Southeast Asia Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.5.6 India Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, 2019-2030
6.6.2 Brazil Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.6.3 Argentina Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, 2019-2030
6.7.2 Turkey Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.7.3 Israel Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.7.4 Saudi Arabia Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
6.7.5 UAE Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, 2019-2030
7 Liposome and Lipid Nanoparticle Finished Pharmaceuticals Companies Profiles
7.1 Johnson & Johnson
7.1.1 Johnson & Johnson Company Summary
7.1.2 Johnson & Johnson Business Overview
7.1.3 Johnson & Johnson Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.1.4 Johnson & Johnson Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.1.5 Johnson & Johnson Key News & Latest Developments
7.2 Sun Pharmaceutical
7.2.1 Sun Pharmaceutical Company Summary
7.2.2 Sun Pharmaceutical Business Overview
7.2.3 Sun Pharmaceutical Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.2.4 Sun Pharmaceutical Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.2.5 Sun Pharmaceutical Key News & Latest Developments
7.3 CSPC
7.3.1 CSPC Company Summary
7.3.2 CSPC Business Overview
7.3.3 CSPC Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.3.4 CSPC Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.3.5 CSPC Key News & Latest Developments
7.4 Kinyond
7.4.1 Kinyond Company Summary
7.4.2 Kinyond Business Overview
7.4.3 Kinyond Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.4.4 Kinyond Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.4.5 Kinyond Key News & Latest Developments
7.5 Teva
7.5.1 Teva Company Summary
7.5.2 Teva Business Overview
7.5.3 Teva Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.5.4 Teva Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.5.5 Teva Key News & Latest Developments
7.6 Fudan-Zhangjiang
7.6.1 Fudan-Zhangjiang Company Summary
7.6.2 Fudan-Zhangjiang Business Overview
7.6.3 Fudan-Zhangjiang Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.6.4 Fudan-Zhangjiang Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.6.5 Fudan-Zhangjiang Key News & Latest Developments
7.7 Zydus Cadila
7.7.1 Zydus Cadila Company Summary
7.7.2 Zydus Cadila Business Overview
7.7.3 Zydus Cadila Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.7.4 Zydus Cadila Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.7.5 Zydus Cadila Key News & Latest Developments
7.8 TTY Biopharma
7.8.1 TTY Biopharma Company Summary
7.8.2 TTY Biopharma Business Overview
7.8.3 TTY Biopharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.8.4 TTY Biopharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.8.5 TTY Biopharma Key News & Latest Developments
7.9 Pacira
7.9.1 Pacira Company Summary
7.9.2 Pacira Business Overview
7.9.3 Pacira Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.9.4 Pacira Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.9.5 Pacira Key News & Latest Developments
7.10 Luye Pharma
7.10.1 Luye Pharma Company Summary
7.10.2 Luye Pharma Business Overview
7.10.3 Luye Pharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.10.4 Luye Pharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.10.5 Luye Pharma Key News & Latest Developments
7.11 Leadiant Biosciences
7.11.1 Leadiant Biosciences Company Summary
7.11.2 Leadiant Biosciences Business Overview
7.11.3 Leadiant Biosciences Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.11.4 Leadiant Biosciences Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.11.5 Leadiant Biosciences Key News & Latest Developments
7.12 Ipsen
7.12.1 Ipsen Company Summary
7.12.2 Ipsen Business Overview
7.12.3 Ipsen Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.12.4 Ipsen Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.12.5 Ipsen Key News & Latest Developments
7.13 Sayre Therapeutics
7.13.1 Sayre Therapeutics Company Summary
7.13.2 Sayre Therapeutics Business Overview
7.13.3 Sayre Therapeutics Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.13.4 Sayre Therapeutics Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.13.5 Sayre Therapeutics Key News & Latest Developments
7.14 Jazz
7.14.1 Jazz Company Summary
7.14.2 Jazz Business Overview
7.14.3 Jazz Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.14.4 Jazz Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.14.5 Jazz Key News & Latest Developments
7.15 Alnylam
7.15.1 Alnylam Company Summary
7.15.2 Alnylam Business Overview
7.15.3 Alnylam Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.15.4 Alnylam Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.15.5 Alnylam Key News & Latest Developments
7.16 Bausch Health
7.16.1 Bausch Health Company Summary
7.16.2 Bausch Health Business Overview
7.16.3 Bausch Health Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.16.4 Bausch Health Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.16.5 Bausch Health Key News & Latest Developments
7.17 Acrotech Biopharma
7.17.1 Acrotech Biopharma Company Summary
7.17.2 Acrotech Biopharma Business Overview
7.17.3 Acrotech Biopharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.17.4 Acrotech Biopharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.17.5 Acrotech Biopharma Key News & Latest Developments
7.18 Takeda
7.18.1 Takeda Company Summary
7.18.2 Takeda Business Overview
7.18.3 Takeda Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.18.4 Takeda Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.18.5 Takeda Key News & Latest Developments
7.19 Chiesi Farmaceutici
7.19.1 Chiesi Farmaceutici Company Summary
7.19.2 Chiesi Farmaceutici Business Overview
7.19.3 Chiesi Farmaceutici Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.19.4 Chiesi Farmaceutici Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.19.5 Chiesi Farmaceutici Key News & Latest Developments
7.20 Gilead Sciences
7.20.1 Gilead Sciences Company Summary
7.20.2 Gilead Sciences Business Overview
7.20.3 Gilead Sciences Liposome and Lipid Nanoparticle Finished Pharmaceuticals Major Product Offerings
7.20.4 Gilead Sciences Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global Market (2019-2024)
7.20.5 Gilead Sciences Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Opportunities & Trends in Global Market
Table 2. Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Drivers in Global Market
Table 3. Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Restraints in Global Market
Table 4. Key Players of Liposome and Lipid Nanoparticle Finished Pharmaceuticals in Global Market
Table 5. Top Liposome and Lipid Nanoparticle Finished Pharmaceuticals Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Share by Companies, 2019-2024
Table 8. Global Companies Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Type
Table 9. List of Global Tier 1 Liposome and Lipid Nanoparticle Finished Pharmaceuticals Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Liposome and Lipid Nanoparticle Finished Pharmaceuticals Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2025-2030
Table 30. Johnson & Johnson Company Summary
Table 31. Johnson & Johnson Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 32. Johnson & Johnson Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 33. Johnson & Johnson Key News & Latest Developments
Table 34. Sun Pharmaceutical Company Summary
Table 35. Sun Pharmaceutical Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 36. Sun Pharmaceutical Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 37. Sun Pharmaceutical Key News & Latest Developments
Table 38. CSPC Company Summary
Table 39. CSPC Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 40. CSPC Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 41. CSPC Key News & Latest Developments
Table 42. Kinyond Company Summary
Table 43. Kinyond Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 44. Kinyond Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 45. Kinyond Key News & Latest Developments
Table 46. Teva Company Summary
Table 47. Teva Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 48. Teva Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 49. Teva Key News & Latest Developments
Table 50. Fudan-Zhangjiang Company Summary
Table 51. Fudan-Zhangjiang Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 52. Fudan-Zhangjiang Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 53. Fudan-Zhangjiang Key News & Latest Developments
Table 54. Zydus Cadila Company Summary
Table 55. Zydus Cadila Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 56. Zydus Cadila Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 57. Zydus Cadila Key News & Latest Developments
Table 58. TTY Biopharma Company Summary
Table 59. TTY Biopharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 60. TTY Biopharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 61. TTY Biopharma Key News & Latest Developments
Table 62. Pacira Company Summary
Table 63. Pacira Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 64. Pacira Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 65. Pacira Key News & Latest Developments
Table 66. Luye Pharma Company Summary
Table 67. Luye Pharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 68. Luye Pharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 69. Luye Pharma Key News & Latest Developments
Table 70. Leadiant Biosciences Company Summary
Table 71. Leadiant Biosciences Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 72. Leadiant Biosciences Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 73. Leadiant Biosciences Key News & Latest Developments
Table 74. Ipsen Company Summary
Table 75. Ipsen Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 76. Ipsen Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 77. Ipsen Key News & Latest Developments
Table 78. Sayre Therapeutics Company Summary
Table 79. Sayre Therapeutics Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 80. Sayre Therapeutics Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 81. Sayre Therapeutics Key News & Latest Developments
Table 82. Jazz Company Summary
Table 83. Jazz Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 84. Jazz Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 85. Jazz Key News & Latest Developments
Table 86. Alnylam Company Summary
Table 87. Alnylam Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 88. Alnylam Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 89. Alnylam Key News & Latest Developments
Table 90. Bausch Health Company Summary
Table 91. Bausch Health Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 92. Bausch Health Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 93. Bausch Health Key News & Latest Developments
Table 94. Acrotech Biopharma Company Summary
Table 95. Acrotech Biopharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 96. Acrotech Biopharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 97. Acrotech Biopharma Key News & Latest Developments
Table 98. Takeda Company Summary
Table 99. Takeda Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 100. Takeda Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 101. Takeda Key News & Latest Developments
Table 102. Chiesi Farmaceutici Company Summary
Table 103. Chiesi Farmaceutici Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 104. Chiesi Farmaceutici Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 105. Chiesi Farmaceutici Key News & Latest Developments
Table 106. Gilead Sciences Company Summary
Table 107. Gilead Sciences Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Offerings
Table 108. Gilead Sciences Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue (US$, Mn) & (2019-2024)
Table 109. Gilead Sciences Key News & Latest Developments
List of Figures
Figure 1. Liposome and Lipid Nanoparticle Finished Pharmaceuticals Segment by Type in 2023
Figure 2. Liposome and Lipid Nanoparticle Finished Pharmaceuticals Segment by Application in 2023
Figure 3. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue in 2023
Figure 8. By Type - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Market Share, 2019-2030
Figure 9. By Application - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Market Share, 2019-2030
Figure 10. By Type - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Market Share, 2019-2030
Figure 12. By Application - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Market Share, 2019-2030
Figure 14. By Region - Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Market Share, 2019-2030
Figure 15. By Country - North America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Market Share, 2019-2030
Figure 16. US Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Market Share, 2019-2030
Figure 20. Germany Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 21. France Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Market Share, 2019-2030
Figure 28. China Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 32. India Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Market Share, 2019-2030
Figure 34. Brazil Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Market Share, 2019-2030
Figure 37. Turkey Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue, (US$, Mn), 2019-2030
Figure 41. Johnson & Johnson Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Sun Pharmaceutical Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. CSPC Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Kinyond Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Teva Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Fudan-Zhangjiang Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Zydus Cadila Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. TTY Biopharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. Pacira Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. Luye Pharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 51. Leadiant Biosciences Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 52. Ipsen Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 53. Sayre Therapeutics Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 54. Jazz Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 55. Alnylam Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 56. Bausch Health Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 57. Acrotech Biopharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 58. Takeda Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 59. Chiesi Farmaceutici Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 60. Gilead Sciences Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
